The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

AOD-9604

HGH Fragment 176-191 · AOD9604 · Frag 176-191

C
Animal replicated
Research chemicalhGH FragmentLipolytic PeptidePeptide
RouteInjectableCompounding pharmacy
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
hGH Fragment 176-191 — Anti-Obesity Drug 9604 — hGH Fragment, Lipolytic Peptide, Peptide.
Why people use it
Used primarily for weight loss and muscle and performance.
What the evidence supports
Multiple binding assays; multiple clinical trials (no GH-like effects)
If you only read one thing

AOD-9604's name literally stands for Anti-Obesity Drug 9604. Its clinical development program was specifically, exclusively designed to demonstrate human fat loss. Six trials. 900+ participants. Rigorous methodology. The pivotal trial failed. No regulatory body has ever approved AOD-9604 for any indication. WADA banned it. The FDA in December 2024 recommended against allowing it to be legally compounded. And it is one of the most widely marketed fat loss peptides in the community, sold with claims of lipolysis and body composition improvement at doses (250-500 mcg SubQ daily) that are roughly 20-60x below the oral doses that failed the pivotal trial. The community is using a compound that tried to prove it burns fat in humans and failed to do so, at doses too low to even replicate the trials that failed.

Check interactions →
Published literature
6human RCTs1human study4animal3in vitro

AOD-9604 had an unusually large clinical program for a peptide fragment, including oral and injectable obesity trials with >900 participants; safety and lack of IGF-1/glucose effects are better supported than durable weight-loss efficacy.

Evidence reality check
Human evidence
7 human studies
6 randomized; 1 observational.
Preclinical base
7 lab signals
4 animal; 3 in-vitro/mechanistic.
Evidence snapshot
Multiple binding assays; multiple clinical trials (no GH-like effects)
From the chapter quick-reference block.

AOD-9604 has the cleanest safety record in this reference and the most direct clinical evidence against its primary claimed application. Both of those facts deserve equal weight.

The central tension resolved: AOD-9604 was designed specifically, explicitly, and professionally to produce human fat loss. Metabolic Pharmaceuticals ran six clinical trials involving more than 900 participants to prove it worked. The pivotal trial failed to demonstrate the primary endpoint. The company terminated development. WADA banned it. The FDA in December 2024 declined to allow it to be legally compounded. The community is using it for fat loss — the exact application it failed to demonstrate — at doses below the doses that failed, in a population completely different from the obese patients who were studied, using a route (SubQ injection) that wasn't even tested in the pivotal trials. The community use of AOD-9604 for fat loss is among the most evidence-unsupported applications in this entire book.

This is not to say AOD-9604 is dangerous — it is among the safest injectable peptides in existence by clinical trial evidence. It is to say that 'safe' and 'effective for fat loss' are different claims, and the evidence for the latter is negative at the clinical trial level. Community users may experience subjective effects or attribute fat loss to AOD-9604 that is actually resulting from improved diet, training, or other compounds in the stack. The absence of proven efficacy does not mean the compound does nothing — it means the controlled evidence doesn't support the primary marketing claim.

The most honest application for AOD-9604 in 2026: the cartilage and joint health application, where the animal data is consistent, the route (local or systemic injection) is more appropriate than oral, and the clinical evidence gap is due to incomplete investigation rather than a failed pivotal trial. For users with osteoarthritis or significant joint damage interested in regenerative approaches, AOD-9604 has a more defensible scientific rationale than for fat loss in lean athletes.

Categories
Weight Loss & MetabolicMuscle & PerformanceHormonal & HPTA
Properties
WADA S2✓ Human RCT
Evidence
CAnimal replicated
Origin
Developed by Professor Frank Ng at Monash University, Melbourne, Australia. Licensed to Metabolic Pharmaceuticals Limited. Designed specifically to capture GH's lipolytic (fat-burning) activity while eliminating its growth-promoting effects by using only the C-terminal fragment that does not bind the classical GH receptor.
The Key Mechanism Claim
AOD-9604 does NOT bind the classical growth hormone receptor (GHR). It does NOT raise IGF-1. It does NOT affect glucose homeostasis. These negatives are among the most consistently supported findings across its clinical trials. What it is proposed to DO: activate lipolysis (fat breakdown) through a separate beta-3 adrenergic receptor-adjacent mechanism in adipose tissue. The lipolytic mechanism in animals is real. The translation to meaningful human fat loss is not established.
THE CLINICAL DEVELOPMENT STORY
Six human clinical trials. Approximately 900 participants total. Conducted 1998-2007. Safety profile indistinguishable from placebo across all trials — the cleanest safety record of any fat-loss compound in this reference. The pivotal Phase IIb OPTIONS trial (n=536, 24 weeks): primary endpoint of weight loss at 12 weeks NOT MET. Development terminated 2007. No regulatory approval from any agency worldwide.
The Dose That 'Worked' in Shorter Trials
Earlier Phase II trials used oral doses of 1 mg/day and showed modest weight loss (~2.6 kg vs 0.8 kg placebo at 12 weeks in one trial — statistically significant but clinically modest). The community interprets this as 'AOD works.' The larger, longer OPTIONS trial was specifically designed to confirm this signal — and it didn't. The 1 mg oral dose is approximately equivalent to ~8-16 mg/day by SubQ injection accounting for oral bioavailability. Community SubQ doses are 0.25-0.5 mg/day — roughly 20-60x below the oral dose that still failed the pivotal trial.
WADA Status
S2 Peptide Hormones, Growth Factors, and Related Substances — BANNED at all times since added to the prohibited list. WADA banned it despite there being no confirmed performance enhancement in humans, reflecting regulatory caution about any GH-derived fragment. Zero tolerance; no TUE pathway.
FDA Status (December 2024)
Removed from FDA Category 2 in 2024 (nominations withdrawn). FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed it December 2024 and recommended against inclusion on the 503A Bulks List. FDA's stated concerns: limited long-term safety data, peptide impurities risk, potential immunogenicity. Not legally compoundable at licensed US 503A pharmacies following this decision.
The Cartilage/OA Application
After the obesity program failed, Metabolic Pharmaceuticals pivoted to exploring AOD-9604 for osteoarthritis — specifically, intra-articular (joint) injection for cartilage repair. Animal models showed chondroprotective effects. This application is more scientifically plausible (local joint injection avoids the systemic dose problem) and has attracted legitimate research interest. The community barely discusses this, focused instead on the failed fat loss application.
Community Dosing
250-500 mcg/day SubQ injection. Typically fasted, morning administration (pre-breakfast). Cycles of 4-12 weeks. These doses are far below any dose that produced even modest effects in clinical trials.
Safety
Clean. Possibly the safest injectable compound in this reference. Six clinical trials, 900+ participants, no significant adverse events differentiated from placebo. No IGF-1 elevation, no glucose effects, no tissue growth. The safety profile is genuinely good. Whether it does anything at community doses is the question.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Sermorelin
C
Same class · Peptide

Genuinely FDA-Approved for 18 Years. Withdrawn for Commercial Reasons, Not Safety. The Gateway Anti-Aging Peptide for a Decade of Compounding Medicine. Put on Category 2 in 2023. Apparently Returned to Category 1 Before the Broader 2026 Reclassification. The Cleanest Safety Profile of Any GH Secretagogue. The Somatostatin Feedback Ceiling That Makes It Physiologically Impossible to Overdose.

Tesamorelin
B
Same class · Peptide

FDA-approved GHRH analog for HIV-associated lipodystrophy, used clinically to reduce visceral adipose tissue via pulsatile GH/IGF-1 signaling.

Cagrilintide
C
Same class · Peptide

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

Check interactions